跳至主要内容
临床试验/NCT02740660
NCT02740660已完成不适用

Effect on Body Composition With Albuterol and Caffeine Versus Placebo in Adolescents: A Pilot Study

Pennington Biomedical Research Center1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2016年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
12
试验地点
1
主要终点
Change in Fat Mass With Caffeine/Albuterol

研究概览

简要总结

The purpose of this study is to determine whether taking a combination of caffeine and albuterol three times per day will increase muscle and decrease fat in your child's body and to determine how these medications make your child feel. Albuterol is approved by the FDA for the treatment of asthma. It is not approved to increase muscle and decrease body fat in children.

详细描述

Previous studies done at Pennington Biomedical have demonstrated that the equivalent of oral albuterol 4mg three times a day (tid) with oral caffeine 100mg tid reduces body fat and increases lean tissue in rodents more than the addition of the effect of the two components separately. The combination of albuterol with caffeine changed body composition without changing food intake. An adult male taking albuterol 4 mg orally tid plus caffeine 100mg orally tid increased lean mass by 1.25% and decreased fat mass by 1.2% over a two month period. These effects are expected to be even greater in a growing adolescent. This pilot project will take the first step towards trying to understanding the safety and potential efficacy of this drug combination. The prospect of using inexpensive medications already approved in the pediatric population for the treatment of asthma as a novel treatment for adolescent obesity addresses a medical need that is presently unmet.

Food restriction in adolescence is not only difficult to accomplish, but it also raises concerns about growth and development. A medication approved for the treatment of obesity in the adolescent age group that improves body composition by reducing body fat and increasing lean tissue without needing to restrict food intake would be a useful tool for physicians who address the treatment of obesity in adolescents. Albuterol is a medication, approved for ages 6 and older, used for the treatment of asthma and has also been shown to increase muscle strength and lean body mass in children with spinal muscular atrophy and in healthy young men during an exercise training program. A drug approved for the treatment of adolescent obesity that increases lean tissue, decreases fat tissue and can be given in conjunction with lifestyle modifications would be welcomed by both pediatricians who treat these adolescents and by adolescents who are stigmatized by their obesity.

A provisional patent has been submitted by Pennington Biomedical Research Center to protect the combination of caffeine and albuterol in a 1:25 ratio for synergistically increasing muscle mass and decreasing fat mass as a potential treatment for obesity in adolescents.

This study will be a double-blinded, randomized, placebo-controlled, pilot study in which subjects will be randomized to receive either placebo or a combination of Albuterol 4 mg and Caffeine 100mg three times per day orally for a total of 8 weeks. Each subject will continue on the study intervention for the entire duration of treatment

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
12 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Healthy males or females with a BMI ≥ 95th percentile
  • Between 12 and 17 years of age inclusive
  • Tanner Stage III and above

排除标准

  • Weigh less than 50 kg
  • Have a family history of sudden death or hypertrophic cardiomyopathy
  • Have a history of unexplained syncope
  • Have a marked baseline prolongation of QT/QTc interval (QTc interval >450 ms), a history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome), or use concomitant medications that prolong the QT/QTc interval
  • Have history of asthma, hypertension, thyroid disease, or significant neurologic disease such as seizure disorder
  • Are pregnant, planning to become pregnant, or nursing. Females who are sexually active must be using adequate contraception.
  • Take a medication known to affect weight or body composition like systemic glucocorticoids, atypical anti-psychotics, or weight loss medications
  • Take beta-stimulators or beta-blockers on a regular basis
  • Take stimulants for attention deficit disorder
  • Take monoamine oxidase inhibitors, tricyclic antidepressants, or diuretics
  • Take any chronic medication that has not had a stable dose for 1 month or longer
  • Have type 1 or type 2 diabetes
  • Have any significant cardiac disease (such as heart failure, arrhythmias, or valve disease), uncontrolled pulmonary disease, chronic liver disease, chronic kidney disease, or chronic infectious disease
  • Have any significant psychiatric illness that is unstable or untreated such as bipolar disorder, severe depression, or severe anxiety
  • Have a history of suicidal ideation
  • Have an allergy or hypersensitivity to albuterol
  • Are unwilling to discontinue caffeine-containing products while in the study
  • Are deemed unfit to participate in the study based on evaluation by the medical investigator

研究组 & 干预措施

Placebo

Placebo Comparator

One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.

干预措施: Placebo (Drug)

Caffeine 100mg / Albuterol 4mg

Experimental

One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.

干预措施: Family weight management counseling (Behavioral)

Caffeine 100mg / Albuterol 4mg

Experimental

One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.

干预措施: Caffeine 100mg / Albuterol 4mg (Drug)

Placebo

Placebo Comparator

One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.

干预措施: Family weight management counseling (Behavioral)

结局指标

主要结局

Change in Fat Mass With Caffeine/Albuterol

时间窗: Baseline, Week 8

DXA Scan of obese adolescents

Change in Lean Mass With Caffeine/Albuterol

时间窗: Baseline, Week 8

DXA Scan of obese adolescents

Change in Weight With Caffeine/Albuterol

时间窗: Baseline, Week 8

次要结局

  • Number of Participants With Adverse Events(Week 2, Week 4, Week 6, Week 8)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Daniel Hsia

Assistant Professor

Pennington Biomedical Research Center

研究点 (1)

Loading locations...

相似试验